| 23004 |
Ropeginterferon alfa-2b |
Besremi® |
Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
NCPE Assessment Process Complete |
15th August 2024 |
 |
| - |
Ropivacaine Readyfusor® |
Ropivacaine Readyfusor® |
For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion. |
Rapid Review Complete |
13th December 2018 |
|
| 21037 |
Roxadustat |
Evrenzo™ |
For the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease. |
Rapid Review Complete |
6th October 2021 |
|
| 25011 |
Rucaparib |
Rubraca® |
Rucaparib (Rubraca®) is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
Rapid Review Complete |
24th March 2025 |
|
| - |
Ruxolitinib |
Jakavi® |
For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. |
Assessment Process Complete |
9th July 2013 |
|
| 20008 |
Ruxolitinib |
Jakavi® |
For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. |
Assessment Process Complete |
21st July 2021 |
|
| 25004 |
Ruxolitinib |
Opzelura® |
Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. |
Rapid Review Complete |
17th February 2025 |
|
